title: Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study.
abstract: OBJECTIVE
  Radiation pneumonitis is the most severe dose-limiting complication in patients receiving thoracic radiation therapy. The aim of this study was to quantify global lung inflammation following radiation therapy using FDG PET/CT.
  
  
  METHODS
  We studied 20 subjects with stage III non-small-cell lung carcinoma who had undergone FDG PET/CT imaging before and after radiation therapy. On all PET/CT studies, the sectional lung volume (sLV) of each lung was calculated from each slice by multiplying the lung area by slice thickness. The sectional lung glycolysis (sLG) was calculated by multiplying the sLV and the lung sectional mean standardized uptake value (sSUVmean) on each slice passing through the lung. The lung volume (LV) was calculated by adding all sLVs from the lung, and the global lung glycolysis (GLG) was calculated by adding all sLGs from the lung. Finally, the lung SUVmean was calculated by dividing the GLG by the LV. The amount of inflammation in the lung parenchyma directly receiving radiation therapy was calculated by subtracting tumor measurements from GLG.
  
  
  RESULTS
  In the lung directly receiving radiation therapy, the lung parenchyma SUVmean and global lung parenchymal glycolysis were significantly increased following therapy. In the contralateral lung (internal control), no significant changes were observed in lung SUVmean or GLG following radiation therapy.
  
  
  CONCLUSIONS
  Global lung parenchymal glycolysis and lung parenchymal SUVmean may serve as potentially useful biomarkers to quantify lung inflammation on FDG PET/CT following thoracic radiation therapy.
authors.affiliation: Department of Radiology, Perelman School of Medicine, University of Pennsylvania, and Hospital of the University of Pennsylvania, Philadelphia, PA, 19104, USA.
authors.forename: Sarah
authors.initials: S
authors.lastname: Abdulla
authors.forename: Ali
authors.initials: A
authors.lastname: Salavati
authors.forename: Babak
authors.initials: B
authors.lastname: Saboury
authors.forename: Sandip
authors.initials: S
authors.lastname: Basu
authors.forename: Drew A
authors.initials: DA
authors.lastname: Torigian
authors.forename: Abass
authors.initials: A
authors.lastname: Alavi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy*; D016022:Case-Control Studies; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000000981:diagnostic imaging / Q000209:etiology; D008168:Lung / Q000528:radiation effects; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D010865:Pilot Projects; D049268:Positron-Emission Tomography; D017564:Radiation Pneumonitis / Q000000981:diagnostic imaging* / Q000209:etiology; D019275:Radiopharmaceuticals / Q000009:adverse effects* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18